Key result
A computed theoretical drug reduced the electrochemical state difference between mutant and wild-type cells by a factor of 36, compared to factors of 4 for mexiletine and 25 for lidocaine.
Population
Computational Markov models of cardiac myocyte action potentials with SCN5A mutations (LQT3)
Comparison
Simulated candidate drug characteristics vs Mexiletine, lidocaine, and wild-type cells
Design
Preclinical
Authors
Loading...
Offers a computational approach to optimize antiarrhythmic selection in LQT3; leaves open whether simulated gains improve clinical outcomes.
Computational modeling of cardiac action potentials can identify optimal drug binding kinetics to correct SCN5A mutations in LQT3 syndrome, outperforming existing drugs like mexiletine and lidocaine in simulations.
Tveito et al. (2011) studied Long-QT (LQT3) syndrome. Computed theoretical drug vs. Mexiletine and lidocaine was evaluated on Difference in the electrochemical state vector between mutant and wild-type cells. A computed theoretical drug reduced the electrochemical state difference between mutant and wild-type cells by a factor of 36, compared to factors of 4 for mexiletine and 25 for lidocaine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: